We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has BellRing Brands (BRBR - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
BellRing Brands is one of 1024 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BellRing Brands is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for BRBR's full-year earnings has moved 1.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, BRBR has gained about 28.7% so far this year. Meanwhile, the Medical sector has returned an average of 4.7% on a year-to-date basis. This means that BellRing Brands is outperforming the sector as a whole this year.
Another stock in the Medical sector, Aldeyra Therapeutics, Inc. (ALDX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 56.4%.
For Aldeyra Therapeutics, Inc. the consensus EPS estimate for the current year has increased 5.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, BellRing Brands belongs to the Medical - Products industry, which includes 87 individual stocks and currently sits at #85 in the Zacks Industry Rank. On average, this group has gained an average of 15% so far this year, meaning that BRBR is performing better in terms of year-to-date returns.
On the other hand, Aldeyra Therapeutics, Inc. belongs to the Medical - Drugs industry. This 171-stock industry is currently ranked #68. The industry has moved +0.5% year to date.
Investors with an interest in Medical stocks should continue to track BellRing Brands and Aldeyra Therapeutics, Inc. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has BellRing Brands (BRBR - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
BellRing Brands is one of 1024 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BellRing Brands is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for BRBR's full-year earnings has moved 1.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, BRBR has gained about 28.7% so far this year. Meanwhile, the Medical sector has returned an average of 4.7% on a year-to-date basis. This means that BellRing Brands is outperforming the sector as a whole this year.
Another stock in the Medical sector, Aldeyra Therapeutics, Inc. (ALDX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 56.4%.
For Aldeyra Therapeutics, Inc. the consensus EPS estimate for the current year has increased 5.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, BellRing Brands belongs to the Medical - Products industry, which includes 87 individual stocks and currently sits at #85 in the Zacks Industry Rank. On average, this group has gained an average of 15% so far this year, meaning that BRBR is performing better in terms of year-to-date returns.
On the other hand, Aldeyra Therapeutics, Inc. belongs to the Medical - Drugs industry. This 171-stock industry is currently ranked #68. The industry has moved +0.5% year to date.
Investors with an interest in Medical stocks should continue to track BellRing Brands and Aldeyra Therapeutics, Inc. These stocks will be looking to continue their solid performance.